Jichen Biotech
济辰生物
elsewhere's corpus does not cover Jichen Biotech as a subject. The only material mentioning the company is background context in Dalton Venture portfolio lists, which name it alongside other investments without describing what the company does, when it was founded, or who runs it . No dedicated article or entity-level information about Jichen Biotech itself appears in the retrieved bundle.
AI-generated — may contain errors, please verify.
Coverage
Steady Steps Toward Renewal, Momentum Into Waves | DTX 2025 Annual Review
Those who walk deeper into the cycle always spot the next beam of light.
Steadfast Progress, Grounded in Action | Dalton Venture's 2024 Year in Review
Looking back at 2024, "adjustment" and "patience" became the defining keywords for venture capital. Yet on the long-distance track of life sciences and medtech, Dalton Venture kept moving forward with steady, deliberate strides. We navigated market fluctuations, caught glimpses of innovation, and helped companies take root and grow through the cycles — writing a new chapter of innovation-driven development with the power of capital.
21st Century Business Herald Interview | Dalton Venture's Sun Qi: Healthcare Is a Long, Snowy Slope — Time for Systematic Bets Is Here
In recent years, as the healthcare industry has yet to emerge from the capital winter, most investment firms have grown more cautious. Dalton Venture, however, has remained active on the investment front thanks to its distinctive strategy and deep understanding of the sector. Recently, **Sun Qi, founding and managing partner of Dalton Venture, sat down with 21st Century Business Herald for an exclusive interview, sharing his unique insights into healthcare industry trends and his confidence and determination to navigate through cycles.**
Spring in Full Bloom, Brilliance Across All Things | Dalton Venture's 2024 CEO Summit Successfully Held
The annual Two Sessions have always been a critical barometer for China's economic trajectory and policy direction. This March, when the government elevated "new quality productive forces" to the top of its work agenda, it sparked intense interest and vigorous debate across industries about this buzzword. As one of the most dynamic drivers of technological innovation and industrial transformation—and a strategic emerging industry that lies at the heart of future industrial planning—how should the medical sector translate new quality productive forces into practice? And where will it steer the development and transformation of the life sciences industry?
